Speech-Language Pathologists in Danvers, MA Accepting Medicare

52 Speech-Language Pathologists found. Showing 41 - 52

Carys Nolin Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 149 Sylvan St, Danvers, MA 01923 Phone: 978-774-7570

Jessica Moore Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 149 Sylvan St, Danvers, MA 01923 Phone: 978-522-5470

Arielle Blake Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 149 Sylvan St, Danvers, MA 01923 Phone: 978-774-7570

Ms. Corrian Elizabeth Farnsworth, MSSP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 90 Lindall St, Danvers, MA 01923 Phone: 978-777-3740

Ioanna Gouzos Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1 Southside Rd, Danvers, MA 01923 Phone: 855-696-3272

Stephanie Elizabeth Kennel Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 149 Sylvan St, Danvers, MA 01923 Phone: 978-522-5459

Sarah Peacock Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 149 Sylvan St, Danvers, MA 01923 Phone: 978-774-7570

Jennifer A Leighton, MA. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2b Mcdermott Farm Rd, Danvers, MA 01923 Phone: 617-270-3297

Elizabeth J Christiansen Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 149 Sylvan St, Danvers, MA 01923 Phone: 978-774-7570

Lauren Cernaro, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 27 Garden St, Danvers, MA 01923 Phone: 978-777-1122

Allison Clinch, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 90 Lindall St, Danvers, MA 01923 Phone: 978-777-3740

Marianne Reape, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 149 Sylvan St, Danvers, MA 01923 Phone: 978-774-7570

News Archive

Protein p53 is the "guardian" of our genome

When DNA damage is present, p53 stops cell division and gives the cell enough time to repair it. If the damage is irreparable, the protein sets off programmed cell death and protects the cells from degeneration.

New combination therapy may help treat anti-estrogen resistant ER+ breast cancer

A study by researchers from the Georgetown Lombardi Comprehensive Cancer Center at Georgetown University Medical Center (GUMC) identifies a potential new combination therapy to "rescue" treatment sensitivity to fulvestrant in estrogen receptor positive breast cancers.

Manchester researchers reveal why ER+ breast cancer women develop resistance to hormone therapy

University of Manchester researchers funded by Breast Cancer Now have discovered a new explanation as to why women with oestrogen receptor positive (ER+) breast cancer develop resistance to hormone treatment, and a potential new approach to overcome the problem.

Vegenics receives IND approval from FDA for VGX-100 Phase I study in late stage cancers

Circadian Technologies Limited announces that its 100% owned subsidiary, Vegenics Pty Ltd, has received approval for its investigational new drug application from the U.S. Food and Drug Administration to initiate clinical trials of VGX-100.

FDA grants Orphan Drug Designation for Accentia's Revimmune to prevent GVHD

Accentia Biopharmaceuticals, Inc. and its majority-owned subsidiary, Biovest International, Inc., today jointly announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revimmune, the Company's proprietary system-of-care based on high-dose administration of Cytoxan, for the prevention of graft-versus-host disease (GVHD) following bone marrow transplant.

Read more Medical News

› Verified 7 days ago

• 1
• 2
• 3(current)